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S 1 
FILLING IN THE CRACKS: 
IMPROVING THE REGULATION 
OF DIRECT-TO-CONSUMER 
GENETIC TESTS 
 
SERRA J. SCHLANGER 
Advances in genetic technology and the increased acceptance of 
genetic testing by the general public have led to the development and sale 
of direct-to-consumer (DTC) genetic tests.1 Genetic testing is one of the 
fastest growing areas of laboratory testing.2 A recent survey found more 
than thirty different DTC genetic testing companies offering genetic tests 
for both health and non-health related purposes.3 These tests range in cost 
from $78 to $68,500.4 The DTC genetic testing companies advertise that an 
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 1. Andrew S. Robertson, Taking Responsibility: Regulations and Protections in Direct-to-
Consumer Genetic Testing, 24 BERKELEY TECH. L.J. 213, 214–15 (2009). 
 2. See BIN CHEN ET AL., DEP‟T OF HEALTH & HUMAN SERVS., CTRS. FOR DISEASE 
CONTROL & PREVENTION, GOOD LABORATORY PRACTICES FOR MOLECULAR GENETIC TESTING 
FOR HERITABLE DISEASES AND CONDITIONS, 58 MORBIDITY & MORTALITY WKLY. REP. 3 
(2009) [hereinafter LABORATORY PRACTICES], available at 
http://www.cdc.gov/mmwr/PDF/rr/rr5806.pdf (describing the rapid growth in the number of 
available genetic tests and the number of laboratories performing genetic testing).  
 3. See GENETICS & PUB. POL‟Y CTR., DTC GENETIC TESTING COMPANIES (Feb. 26, 2010) 
[hereinafter DTC GENETIC TESTING COMPANIES], available at 
http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=137 (compiling a list 
of DTC genetic testing companies and information on what tests each company offers). 
 4. See e.g., Low Cost At Home DNA Paternity Test, HOMEDNA, https://www.homedna.com 
(last visited Mar. 1, 2011) (advertising a $78 DNA Home Paternity Testing System); Ryan 
McBride, Knome Challenged to Keep in Step With Falling Genetic Sequencing Prices, 
XCONOMY, Jan. 1, 2010, http://www.xconomy.com/boston/2010/01/20/knome-challenged-to-
keep-in-step-with-falling-genetic-sequencing-prices/?single_page=true (detailing Knome‟s 
complete genetic sequence service price decrease from $350,000 in 2008 to the current price of 
$68,500). 
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individual‟s genetic profile can be used to find love,5 to fill in a family 
tree,6 to determine genetic athletic advantages,7 to assist in weight loss,8 
and to discover individual genetic risk for forty-seven different diseases and 
traits.9 Although more than 1,200 genetic tests, covering a wide variety of 
issues and conditions, are currently available on the consumer market, the 
Food and Drug Administration (FDA) has approved fewer than a dozen of 
them.10 
DTC genetic tests currently fall through the regulatory cracks because 
several governmental agencies oversee individual aspects and components 
of genetic testing, but no single agency covers all genetic tests.11 This 
apparent lack of cohesive regulation is startling because the general public 
widely believes that the government comprehensively regulates genetic 
testing.12 Unaware of the minimal regulation and oversight, consumers may 
have misplaced confidence in the claims made by those selling genetic tests 
and may be unaware that a particular genetic test may not provide 
meaningful results or be based on accurate science.13 The absence of a 
comprehensive regulatory scheme has created an opportune environment 
for genetic test makers to directly target consumers and to encourage the 
purchase of genetic tests with unproven medical value.14 The current 
limited regulatory structure legally fails to protect the rights and interests of 
vulnerable individuals.15 
 
 5. GENEPARTNER.COM, http://www.genepartner.com (last visited Mar. 1, 2011). 
 6. Discover DNA Ancestry and Genetic History with our DNA Test, 23ANDME, 
https://www.23andme.com/ancestry/ (last visited Mar. 1, 2011). 
 7. ATLAS FIRST SPORTGENE TEST, http://www.atlasgene.com (last visited Mar. 1, 2011).  
 8. INHERENT HEALTH, WEIGHT MANAGEMENT, http://www.inherenthealth.com/our-
tests/weight-management.aspx (last visited Mar. 1, 2011). 
 9. DECODEME, http://www.decodeme.com (last visited Mar. 1, 2011). 
 10. Joan L. McGregor, Why John Stuart Mill Would Support Restriction on DTC Marketing 
of Genetic Tests, 8 AM. J. BIOETHICS 9, 9 (2008). 
 11. Rebecca Antar Novick, Note, One Step at a Time: Ethical Barriers to Home Genetic 
Testing and Why the U.S. Health Care System Is Not Ready, 11 N.Y.U. J. LEGIS. & PUB. POL‟Y 
621, 624 (2008). 
 12. Consumer-Directed Promotion of Regulated Medical Products: Public Hearing Docket 
No. 2005N-0354 (2005) (comments of Gail Javitt, Genetics and Public Policy Center), available 
at http://www.dnapolicy.org/resources/FDA_Testimony.pdf. 
 13. U.S. GOV‟T ACCOUNTABILITY OFFICE, GAO-06-977T, NUTRIGENETIC TESTING TESTS 
PURCHASED FROM FOUR WEB SITES MISLEAD CONSUMERS, 2 (2006) (prepared statement of 
Gregory Kutz, Managing Director of Forensic Audits and Special Investigations for At Home 
DNA Tests: Marketing Scam or Medical Breakthrough: Hearing Before the S. Special Comm. on 
Aging, 109th Cong. (2006)); Gail H. Javitt & Kathy Hudson, Federal Neglect: Regulation of 
Genetic Testing, 22 ISSUES SCI. & TECH. 59, 62 (2006), available at 
http://www.dnapolicy.org/resources/Issues_in_Science_and_Technology.pdf. 
 14. Javitt & Hudson, supra note 13, at 62. 
 15. Sjef Gevers, The Marketing of Health Products, With Special Reference to Do-It-Yourself 
Tests, 22 MED. & L. 199, 206 (2003). 
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Part I of this Comment explains the unique nature of genetic material 
and the concerns that arise when individuals undergo genetic testing. These 
concerns focus on test result accuracy, the influence of genetic information 
on medical practice, adequate genetic counseling, and the psychological 
impact of genetic information.16 Part I also introduces the current state of 
clinical and DTC genetic test regulation and examines the different 
regulatory approaches taken by individual states.17 Part I identifies the 
FDA, the Federal Trade Commission (FTC), and the Centers for Medicare 
and Medicaid Services (CMS) as the three federal agencies that have the 
greatest potential to regulate DTC genetic tests and assesses the agencies‟ 
current regulations.18  
The FDA has previously considered and managed similar concerns 
about test result accuracy, adequate result counseling, and the psychological 
impact of test results during the development of the HIV home test kit.19 
Part II of this Comment examines the contentious development of the HIV 
home test kit and focuses on the arguments about home test kit accuracy 
and the availability of pre- and post-test counseling for home test kit 
users.20 Part II also describes the HIV home test kit that received FDA 
approval in 1996.21 
Part III of this Comment looks forward to potential new developments 
and solutions for the current patchwork system of DTC genetic test 
regulation. Part III suggests that the FDA should look to the HIV home test 
kit counseling requirement as a model to help combat current concerns 
about the impact of DTC genetic tests on individual health decision 
making.22 Part III also recommends that the FTC and CMS increase their 
efforts to protect consumers from false and misleading advertisements for 
DTC genetic tests.23 Although this Comment focuses on DTC genetic test 
 
 16. See Robert M. Cook-Deegan, NIH-DOE Joint Working Group on Ethical, Legal, and 
Social Issues Established, HUMAN GENOME NEWS (Human Genome Program, U.S. Dep‟t of 
Energy, Washington, D.C.), May 1990, available at 
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/hgn/v2n1/05elsi.shtml 
(identifying nine topics and issues that may arise with genome technology development); Human 
Genome Project, Ethical, Legal, and Social Issues – Genome Research, U.S. DEP‟T OF ENERGY 
OFFICE OF SCI., http://www.ornl.gov/sci/techresources/Human_Genome/elsi/elsi.shtml (last 
visited Mar. 1, 2011) (raising questions related to societal concerns about the availability genetic 
information). 
 17. See infra Part I.A. 
 18. See infra Part I.B. 
 19. Ronald Bayer et al., Testing for HIV Infection at Home, 332 NEW ENG. J. MED. 1296 
(1995). 
 20. See infra Part II.A. 
 21. See infra Part II.B. 
 22. See infra Part III.A. 
 23. See infra Parts III.B–C. 
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regulation, the proposed regulatory improvements may also impact and 
improve the quality of physician-provided genetic tests and can help 
provide patients and physicians with greater confidence in all genetic 
testing.24 
I. CURRENT CONCERNS AND THE STATE OF REGULATION 
Genetics is the science of biological variation and includes the science 
and practice of diagnosis, prevention, and management of genetic 
disorders.25 Since the double helix structure of DNA was first described in 
1953,26 modern genetic research has expanded as the scientific and medical 
communities try to gain a better understanding of the genes that control 
human inherited traits.27 Currently a wide variety of genetic tests can 
provide information for more than 1,500 diseases.28  
A genetic test is defined as “[t]he analysis of human DNA, RNA, 
chromosomes, proteins, and certain metabolites in order to detect inherited 
disease-related genotypes, mutations, phenotypes, or karyotypes for clinical 
purposes.”29 Such clinical purposes include identifying carriers of genetic 
diseases, prenatal and post-birth testing for disease-causing genetic 
abnormalities, predicting an individual‟s risk of disease development, 
predicting an individual‟s response to specific medications, and establishing 
 
 24. Javitt & Hudson, supra note 13, at 66. 
 25. Mary B. Mahowald, Genetic Technologies and Their Implications for Women, 3 U. CHI. 
L. SCH. ROUNDTABLE 439, 440 (1996). 
 26. James D. Watson & Francis H.C. Crick, A Structure for Deoxyribose Nucleic Acid, 171 
NATURE 737, 737 (1953). In addition to describing the structure of DNA, the authors also note 
that the structure “immediately suggests a possible copying mechanism for the genetic material.” 
Id. 
 27. See generally James D. Watson & Francis H.C. Crick, Genetical Implications of the 
Structure of Deoxyribonucleic Acid, 171 NATURE 964, 966 (1953) (explaining Watson and 
Crick‟s original hypothesis about how the structure of DNA provides a template for genetic 
inheritance). 
 28. Daniel Schlein, New Frontiers for Genetic Privacy Law: The Genetic Information 
Nondiscrimination Act of 2008, 19 GEO. MASON U. CIV. RTS. L.J. 311, 311 (2009). 
 29. PROMOTING SAFE AND EFFECTIVE GENETIC TESTING IN THE UNITED STATES: FINAL 
REPORT OF THE TASK FORCE ON GENETIC TESTING, 6 (Neil A. Holtzman & Michael S. Watson 
eds., 1998) [hereinafter FINAL REPORT], available at http://www.genome.gov/10001733. 
Genotype refers to an individual‟s collection of genes. Talking Glossary of Genetic Terms, NAT‟L 
HUMAN GENOME RESEARCH INST., http://www.genome.gov/glossary/index.cfm (last visited Mar. 
1, 2011) [hereinafter Glossary]. One half of an individual‟s genes are inherited from the mother; 
the other half is inherited from the individual‟s father. FINAL REPORT, supra note 29, at 178. A 
mutation is a change in an individual‟s DNA sequence that may be caused by DNA copying 
mistakes, exposure to radiation or chemicals, or infection by viruses. Glossary, supra note 29. 
Phenotype refers to an individual‟s observable traits and characteristics that result from the 
interaction of the genotype with the environment. Id.; FINAL REPORT, supra note 29, at 179. 
Karyotype refers to an individual‟s collection of chromosomes or a laboratory technique used to 
look for abnormal chromosome numbers or structure. Glossary, supra note 29. 
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an individual‟s clinical diagnosis or prognosis.30 At first, genetic testing 
was only offered and available through health care providers,31 so genetic 
testing companies marketed their services to the providers.32 However, by 
2002, as the potential market for genetic testing became more apparent, 
companies began to market their genetic tests directly to consumers.33 Early 
advertisements used themes of fear, hope, and peace of mind to encourage 
women and certain ethnic groups to request genetic testing from their 
physicians.34 These advertisement themes continue to be used today in an 
expanded genetic testing market that now encompasses more individuals 
and a wider variety of conditions.35 
Today, the majority of genetic tests are still only available in health 
care settings; however, some companies have made genetic tests available 
directly to consumers, primarily though the Internet.36 The Internet 
currently hosts more than thirty different DTC genetic testing companies 
that offer a wide variety of genetic testing services.37 These tests are 
advertised for both medical and non-medical purposes and can be grouped 
into four broad categories: 1) individual susceptibility to disease, 2) 
nutritional and metabolic assessments, 3) genetic linkage to individual traits 
or characteristics, and 4) ancestry information.38 
 
 30. FINAL REPORT, supra note 29, at 6; Gail H. Javitt et al., Direct-to-Consumer Genetic 
Tests, Government Oversight, and the First Amendment: What the Government Can (and Can’t) 
Do to Protect the Public’s Health, 57 OKLA. L. REV. 251, 257 (2004). A carrier is a person who 
has inherited a disease-causing gene from one parent and a normal gene from the other parent. 
FINAL REPORT, supra note 29, at 177. Generally a carrier suffers no ill effects of the disease-
causing gene. Id. 
 31. Cynthia Marietta & Amy L. McGuire, Direct-to-Consumer Genetic Testing: Is It the 
Practice of Medicine?, 37 J.L. MED. & ETHICS 369, 369 (2009). 
 32. See Javitt et al., supra note 30, at 262 (“The major laboratories generally sell their testing 
services to health care providers and hospitals, not directly to consumers.”). 
 33. See Sarah E. Gollust et al., Limitations of Direct-to-Consumer Advertising for Clinical 
Genetic Testing, 288 JAMA 1762, 1762 (2002) (recounting some of the advertisements for genetic 
tests and services that appeared in the popular press). As early as 2001, advertisements for breast 
cancer genetic testing appeared in Broadway show programs and on television. Ellen Matloff & 
Arthur Caplan, Direct to Confusion: Lessons Learned from Marketing BRCA Testing, 8 AM. J. 
BIOETHICS 5, 6 (2008).  
 34. Gollust et al., supra note 33, at 1762–63. 
 35. See Matloff & Caplan, supra note 33, at 6–7 (discussing Myriad Genetics DTC “public 
awareness campaign”); McGregor, supra note 10, at 9 (reporting the “amazing array of issues” 
covered by DTC genetic tests). 
 36. Javitt et al., supra note 30, at 262. 
 37. DTC GENETIC TESTING COMPANIES, supra note 3. 
 38. Marietta & McGuire, supra note 31, at 369. The second and fourth categories, nutritional 
and metabolic assessments and ancestry information, generally fall outside the use of genetic 
testing for medical purposes. Other non-medical uses of genetic tests include paternity and sibling 
testing. This Comment will primarily address issues related to the use of genetic testing for 
medical purposes. 
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Virtually all information about an individual‟s health and physical 
well-being can be considered genetic information because DNA underlies 
almost every aspect of human health.39 However, genetic information is 
fundamentally different from other forms of health information, and genetic 
testing differs from other diagnostic tests and medical treatments.40 Genetic 
test results are often used primarily for predictive purposes even though the 
probability that an individual will develop a condition in the future is 
uncertain.41 A negative test result only indicates the absence of a particular 
gene sequence that is linked to a disease or condition, so negative test 
results do not always rule out the possibility of future disease occurrence.42 
Similarly, positive test results do not necessarily mean that an individual 
will develop a disease or condition because the positive result merely 
indicates the presence of a particular gene sequence that is associated with 
the occurrence of a disease or condition.43 Even in circumstances where an 
individual‟s positive test result directly correlates to future disease 
development, the positive test result does not indicate when or how the 
disease will develop, or the severity of the disease manifestation.44 
Furthermore, genetic test results may have limited use because there are 
currently few interventions available to improve the outcome of most 
genetically linked diseases.45 
Although genetic information is unique to each individual, it is also 
inherently familial because genes are the basis of hereditary traits that pass 
from one generation to the next.46 Genetic testing inevitably uncovers 
information about an individual‟s genetic relatives,47 which may force those 
who undergo these tests to confront complex questions about the disclosure 
 
 39. OFFICE OF SCI., U.S. DEP‟T OF ENERGY, DOE/SC-0083, GENOMICS AND ITS IMPACT ON 
SCIENCE AND SOCIETY, 5 (2008), available at 
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/primer2001/primer11.pdf; Ellen 
Wright Clayton, Ethical, Legal, and Social Implications of Genomic Medicine, 349 NEW. ENG. J. 
MED. 562, 562 (2003). 
 40. Javitt et al., supra note 30, at 260. 
 41. Katherine Wasson, Consumer Alert: Ethical Issues Raised By the Sale of Genetic Tests 
Directly to Consumers, 8 AM. J. BIOETHICS 16, 17 (2008).  
 42. FINAL REPORT, supra note 29, at 3; Jennifer A. Gniady, Note, Regulating Direct-to-
Consumer Genetic Testing: Protecting the Consumer Without Quashing a Medical Revolution, 76 
FORDHAM L. REV. 2429, 2435 (2008). 
 43. FINAL REPORT, supra note 29, at 3; Javitt et al., supra note 30, at 260. 
 44. Javitt et al., supra note 30, at 260–61. 
 45. FINAL REPORT, supra note 29, at 2–3; Gniady, supra note 42, at 2435. 
 46. See Javitt et al., supra note 30, at 261 (describing how related individuals may be carriers 
for genetic traits). 
 47. Patricia Roche, Caveat Venditor: Protecting Privacy and Ownership Interests in DNA, in 
HUMAN DNA: LAW AND POLICY INTERNATIONAL AND COMPARATIVE PERSPECTIVES 33, 34 
(Bartha M. Knoppers ed., 1997). 
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of test results to their relatives.48 In addition, individuals may be pressured 
by genetic relatives to undergo testing that they would not otherwise 
consider.49 
Though genetic test results may not be more informative than other 
traditional forms of health information, the general public and media often 
perceive genetic information as infallible.50 Individuals who undergo 
genetic testing have a risk of receiving false positive or false negative 
results, which may lead them to make potentially harmful choices based on 
false information.51 Despite the predictive quality of genetic testing, 
individuals often interpret their results as a view of their medical destiny.52 
In addition genetic information has “historically been used as the basis for 
categorizing members of society” and may still be used for purposes of 
discrimination.53 
Concerns about the unique nature of genetic information and genetic 
testing can be generally categorized as relating to: result accuracy and the 
influence of genetic information on medical practice; adequate genetic 
counseling and the psychological impact of genetic information; personal 
privacy, confidentiality, and fair use of genetic information; and the 
commercialization of genetic products.54 In the 1990s, an official Task 
Force on Genetic Testing55 raised concerns that certain genetic tests were 
made available to patients before the tests were determined “to be safe, 
effective, and useful.”56 Today, many health care providers echo these 
concerns and worry that the genetic tests marketed directly to consumers 
are not as accurate, valid, or reliable as tests provided in a clinical setting.57 
Despite concerns about test result accuracy, “DTC genetic tests are 
becoming more widely utilized [by consumers] due to their convenience 
 
 48. Id.; Javitt et al., supra note 30, at 261. 
 49. Gevers, supra note 15, at 202. 
 50. Javitt et al., supra note 30, at 261. 
 51. Wasson, supra note 41, at 17. “A false positive test indicates a person has X when he does 
not and false negative tests indicates a person is free of X when he actually has it.” Id. 
 52. Clayton, supra note 39, at 563. See also Is your DNA your destiny?, NAVIGENICS, 
http://www.navigenics.com/visitor/genetics_and_health/dna_basics/is_dna_destiny/ (last visited 
Mar. 1, 2011). 
 53. Roche, supra note 47, at 34. 
 54. Cook-Deegan, supra note 16. These concerns were first identified by a joint working 
group established by the National Institutes of Health (NIH) and the Department of Energy (DOE) 
to address policy issues in response to the accelerating pace of scientific development and 
genomic technology following the completion of the Human Genome Project. Id. 
 55. The Task Force on Genetic Testing was an official government advisory group created by 
the NIH-DOE working group and charged with the task of making recommendations to assure the 
public that genetic tests are safe and effective. FINAL REPORT, supra note 29, at 4. 
 56. Id. at xii; Gregorio M. Garcia, The FDA and Regulation of Genetic Tests: Building 
Confidence and Promoting Safety, 48 JURIMETRICS J. 217, 219 (2008). 
 57. Wasson, supra note 41 at 17. 
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and confidential nature.”58 Individual consumers worried about the 
wrongful disclosure of their genetic information may choose to use DTC 
genetic tests because the results are reported directly to their homes.59 
Though few cases of discrimination based on an individual‟s genetic 
information have been reported, many consumers and patients are wary of 
the potential for such misuse.60 Avoiding the traditional clinical setting 
prevents genetic test results from being included in an individual‟s medical 
records and increases that individual‟s protection from the potential 
disclosure of genetic test results to employers or insurance companies.61 
The lack of physician involvement in DTC genetic testing is 
troublesome to many health care professionals who worry that individuals 
who receive their genetic test results will not understand the complex nature 
of these results.62 Patients who undergo clinical genetic testing traditionally 
receive genetic counseling from their health care provider who can explain 
the probabilistic nature of genetic test results.63 Without any counseling, 
individuals may be confused by their results because the absence of a 
particular gene does not ensure that the individual will not develop a 
particular disease.64 Absent genetic counseling, individuals may also face 
unnecessary stress about their results because the presence of a particular 
gene does not guarantee that the individual will develop a particular 
condition.65 There is evidence that even when individuals receive 
counseling, “[patients] are unable to understand the explanations of test 
results and lack an understanding of both the risks of developing specific 
 
 58. Lauren Solberg, Note, Over the Counter but Under the Radar: Direct-to-Consumer 
Genetics Tests and FDA Regulation of Medical Devices, 11 VAND. J. ENT. & TECH. L. 711, 714–
15 (2009). 
 59. Wasson, supra note 41, at 18. 
 60. Schlein, supra note 28, at 315. 
 61. Wasson, supra note 41, at 18. The disclosure of an individual‟s personal health 
information, including genetic test results, by a health care provider is regulated by the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA). Health Insurance Portability and 
Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936 (1996) (codified in scattered 
sections of 26, 29, & 42 U.S.C.). The use of genetic information by employers and insurance 
companies is limited by the Genetic Information Nondiscrimination Act (GINA). Genetic 
Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881 (2008) (to be 
codified in scattered sections of 26, 29, & 42 U.S.C.). GINA prohibits group health plans from 
adjusting premium or contribution amounts on the basis of genetic information. §§ 101–106, 122 
Stat. at 883–905. GINA also prohibits employers from using genetic information to make 
decisions regarding hiring, firing, job placement and promotions in addition to regulating how 
employers may acquire an employee‟s genetic information. §§ 201–213, 122 Stat. at 905–920. 
 62. Audrey Chapman, DTC Marketing of Genetic Tests: The Perfect Storm, 8 AM. J. 
BIOETHICS 10, 10 (2008); Wasson, supra note 41, at 17–18. 
 63. See Novick, supra note 11, at 635–36 (describing the discussions genetic counselors have 
with patients deciding to undergo genetic testing). 
 64. FINAL REPORT, supra note 29, at 3. 
 65. Id. 
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diseases and the role that the environmental factors play.”66 A genetic 
predisposition to a condition does not indicate how severe the symptoms 
will be, or how the individual will respond to available treatments.67 
Opponents of DTC tests assert that individuals who utilize these tests are 
particularly likely to face adverse effects “when the interpretation of test 
results requires specific expertise, [when] the outcome of the test results in 
options that require expert advice, and [when] the potential psychological 
impact makes professional support necessary.”68 Additionally, opponents 
argue that consumers need counseling to understand their genetic test 
results and to best utilize the results when making important health care 
decisions based on those results.69 Supporters of DTC genetic testing argue 
that many physicians are insufficiently prepared to interpret genetic test 
results,70 and that individuals have a right to access their own genetic 
information.71 The increased use of genetic tests and the emergence of DTC 
genetic tests have stimulated further debate about the regulation of genetic 
tests.72  
A. State Regulation 
In 2007 and 2008 New York and California sent “cease and desist” 
letters to thirty-one genetic testing companies that engage in DTC sales.73 
The letters targeted companies that provide genetic tests directly to 
consumers without the involvement of a licensed physician74 and stated that 
the companies “need licenses to solicit specimens of DNA from state 
residents.”75 Following these letters, California granted licenses to a limited 
number of these companies.76 California and New York are among the 
 
 66. Gniady, supra note 42, at 2448. 
 67. Id. at 2435. 
 68. Gevers, supra note 15, at 202. 
 69. Wasson, supra note 41, at 17. For example, a woman who has a genetic test result that 
indicates a predisposition to the development of breast cancer may choose to undergo prophylactic 
breast surgery in order to reduce her risk of disease development. 
 70. Gniady, supra note 42, at 2448. 
 71. Wasson, supra note 41, at 17. 
 72. See generally At Home DNA Tests: Marketing Scam or Medical Breakthrough: Hearing 
Before the S. Special Comm. on Aging, 109th Cong. 1–2 (2006) (statement of Sen. Gordon H. 
Smith, Chairman, S. Special Comm. on Aging) (describing concerns regarding the oversight of 
and science behind DTC genetic tests). 
 73. Jane E. Brody, Buyer Beware of Home DNA Tests, N.Y. TIMES, Sept. 1, 2009, 
http://www.nytimes.com/2009/09/01/health/01brod.html?_r=1&nl=health&emc=healthupdateemb
3#; Andrew Pollack, Gene Testing Questioned by Regulators, N.Y. TIMES, June 26, 2008, 
http://www.nytimes.com/2008/06/26/business/26gene.html?_r=1. 
 74. Robertson, supra note 1, at 213. 
 75. Brody, supra note 73. 
 76. Robertson, supra note 1, at 213. 
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twelve states that currently allow limited DTC testing.77 While some states 
limit the use of DTC testing by focusing on specific tests that may be 
ordered directly by consumers,78 other states limit the use of DTC tests to 
those tests ordered by licensed practitioners, physicians, or authorized 
professionals listed in the statute and further require that results only be 
reported to the authorized person who requested the test.79 
Twenty-five states and the District of Columbia allow DTC testing 
without any restriction,80 while thirteen states prohibit all DTC testing.81 
Many states that prohibit all DTC testing specify that the ordering of tests is 
limited to licensed physicians or other professionals authorized by law to 
make medical diagnoses.82 The majority of states that allow unrestricted 
DTC testing have no applicable state statute or regulation that addresses 
these tests,83 which effectively allows DTC testing to occur in the state.84 
Only five states that allow unrestricted DTC testing and the District of 
Columbia have laws that may be interpreted to apply to DTC testing.85 
These laws generally do not address DTC testing directly, but instead focus 
on the need for informed consent86 or the need for a physician to receive 
and interpret the results.87 Although state restrictions that require a 
physician order the test and receive the test results seem to indicate a level 
of validity in the testing process, DTC genetic testing companies that wish 
 
 77. GENETICS & PUB. POL‟Y CTR., SURVEY OF DIRECT-TO-CONSUMER TESTING STATUTES 
AND REGULATIONS (June 2007) [hereinafter DTC STATUTE SURVEY], available at 
http://www.dnapolicy.org/resources/DTCStateLawChart.pdf. The other states that allow limited 
DTC testing are: Arizona, Colorado, Florida, Illinois, Maine, Maryland, Massachusetts, Nevada, 
New Jersey, and Oregon. Id. 
 78. E.g., ME. REV. STAT. ANN. tit. 22, § 2030 (2004); NEV. REV. STAT. ANN. § 652.190 
(2008). 
 79. E.g., ARIZ. REV. STAT. ANN. § 36-470 (2009); CAL. HEALTH & SAFETY CODE § 123148 
(2006); FLA. STAT. ANN. §§ 483.181(1)–(2) (2006 & Supp. 2011); 210 ILL. COMP. STAT. 25/7-101 
to -102 (2008). 
 80. DTC STATUTE SURVEY, supra note 77. The states that allow DTC testing without 
restriction include: Alaska, Arkansas, Delaware, Indiana, Iowa, Kansas, Louisiana, Minnesota, 
Mississippi, Missouri, Montana, Nebraska, New Mexico, North Carolina, North Dakota, Ohio, 
Oklahoma, South Dakota, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and 
Wisconsin. Id. 
 81. Id. The states that prohibit all DTC testing include: Alabama, Connecticut, Georgia, 
Hawaii, Idaho, Kentucky, Michigan, New Hampshire, Pennsylvania, Rhode Island, South 
Carolina, Tennessee, and Wyoming. Id. 
 82. E.g., GA. CODE ANN. § 31-22-4(a) (2009); TENN. CODE ANN. § 68-29-121 (2006 & Supp. 
2010). 
 83. DTC STATUTE SURVEY, supra note 77. Twenty of the twenty-five states that allow DTC 
testing have state laws that are “silent on the issue.” Id. 
 84. Robertson, supra note 1, at 224. 
 85. DTC STATUTE SURVEY, supra note 77. Nebraska, North Carolina, Virginia, Washington, 
and Wisconsin have state laws that may be interpreted to apply to DTC testing. Id. 
 86. E.g., NEB. REV. STAT. § 71-551 (2009). 
 87. E.g., WASH. ADMIN. CODE § 246-338-070 (2009). 
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to circumvent these requirements often have “an arrangement with a 
physician whose name is used to order tests and report results to the 
consumer.”88 However, affiliation with a physician does not necessarily 
indicate that the test is accurate or that the patient receives counseling about 
the test results.89 Similarly, having a doctor working under a contract with 
the company review the consumer‟s test orders before the specimens are 
given to the testing laboratory is not the same as having the individual‟s 
physician order the tests.90 
In addition to regulating the provision of DTC genetic tests, states can 
also use their unfair or deceptive trade practice statutes to protect 
consumers.91 Although every state has enacted laws to generally regulate 
false advertising and deceptive marketing practices,92 none of the states 
have laws that directly address the advertising or marketing of genetic 
testing.93 Instead, many of the states‟ broad statutes prohibit deceptive trade 
practices that may confuse the consumer‟s awareness of the “source, 
sponsorship, approval or certification of goods or services” or that 
“represent that goods or services have sponsorship, approval, 
characteristics, ingredients, uses, benefits or quantities that they do not 
 
 88. Robertson, supra note 1, at 224–25. This practice is especially common with DTC genetic 
test providers who do business through the Internet. Id. The use of the Internet also enables third 
party DTC genetic test companies to sell genetic tests that are supposed to be only clinically 
available directly to consumers. Stuart Hogarth et al., Direct-to-Consumer Genetic Testing: Legal, 
Ethical, and Policy Issues, 9 ANN. REV. GENOMICS & HUMAN GENETICS 161, 164 (2008) 
(explaining that although Myriad Genetics does not sell its tests directly to patients, consumers are 
able to purchase the tests from DNA Direct, a third party DTC genetic test company that uses its 
own healthcare providers to order the test from Myriad). 
 89. Robertson, supra note 1, at 225. See also Turna Ray, CDC Advises Docs to Inform 
Patients of Limitations of DTC Gene Scans, PHARMACOGENOMICS REP., July 29, 2010, 
http://www.genomeweb.com/dxpgx/cdc-advises-docs-inform-patients-limitations-dtc-gene-scans 
(explaining that even though some DTC companies have partnered with “wellness groups and 
doctors,” the CDC believes that the tests are “lacking in terms of clinical validity and clinical 
utility.”). 
 90. See Pollack, supra note 73. As the former director of the Genetics and Public Policy 
Center at Johns Hopkins University said “„some doc on the payroll at Genes R Us‟ is not the same 
as a personal physician.” Id. “A physician working for a company selling the [DTC genetic] tests 
is clearly not well situated to look after a patient‟s best interest” when providing advice about the 
need for the test or when ordering the test. David Magnus et al., Direct-to-Consumer Genetic 
Tests: Beyond Medical Regulation?, 1 GENOME MED. 17 (2009), available at 
http://genomemedicine.com/content/1/2/17. 
 91. GENETICS & PUB. POL‟Y CTR., SURVEY OF STATE FALSE ADVERTISING LAWS 1 (August 
2009) [hereinafter FALSE ADVERTISING SURVEY], available at 
http://www.dnapolicy.org/resources/Prince_StateFalseAdvertisingLaws.pdf.  
 92. Alan S. Brown & Larry E. Hepler, Comparison of Consumer Fraud Statutes Across the 
Fifty States, 55 FDCC Q. 263, 263 (2005).  
 93. FALSE ADVERTISING SURVEY, supra note 91, at 1. 
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have . . . .”94 Only two state statutes specifically address scientific and 
clinical advertising claims.95 California‟s statute prohibits false and 
misleading advertising claims that “purport to be based on . . . clinical 
evidence.”96 Nevada‟s statute states that  
a person engages in a „deceptive trade practice‟ when . . . 
he or she makes an assertion of scientific, clinical or 
quantifiable fact in an advertisement which would cause a 
reasonable person to believe that the assertion is true, 
unless, at the time the assertion is made, the person making 
it has possession of factually objective scientific, clinical or 
quantifiable evidence which substantiates the assertion[.]97 
Furthermore, California‟s statute is the only one to specify that the 
provisions apply to advertisements over the Internet, in addition to those in 
more traditional publications.98 Despite broad trade practice laws that 
provide states with another way to protect consumers, only one attorney 
general has initiated an investigation into the claims made in DTC genetic 
test advertisements.99 
During the past decade, the number of states that allow some form of 
DTC testing has increased.100 Individual states have the authority to strictly 
regulate genetic tests,101 however, the majority of current state regulations 
do not address the major concerns about test accuracy or appropriate 
counseling for individuals who undergo genetic testing.102 The enforcement 
 
 94. DEL. CODE ANN. tit. 6, § 2532 (2005); GA. CODE ANN. § 10-1-372 (2009); ME. REV. 
STAT. ANN. tit. 10, § 1212 (2009). Many states, including Alabama, Alaska, Colorado, Delaware, 
Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Michigan, Minnesota, 
Mississippi, Nebraska, New Hampshire, Oregon, Pennsylvania, Tennessee, Texas, Utah, and West 
Virginia, have adopted provisions based on the Uniform Deceptive Trade Practices Act or 
Uniform Consumer Sales Practices Act, and therefore have almost identical language in their state 
statutes. Brown & Hepler, supra note 92, at 266–68, 290–308 (2005). See also FALSE 
ADVERTISING SURVEY, supra note 91, at 1–32 (highlighting the applicable text in each state‟s 
statute). 
 95. FALSE ADVERTISING SURVEY, supra note 91, at 1. 
 96. CAL. BUS. & PROF. CODE § 17508 (2008). 
 97. NEV. REV. STAT. ANN. § 598.0925 (2010). 
 98. CAL. BUS. & PROF. CODE § 17500 (2008). 
 99. FALSE ADVERTISING SURVEY, supra note 91, at 1; Andrew Pollack, A Genetic Test That 
Very Few Need, Marketed to the Masses, N.Y. TIMES, Sept. 11, 2007, 
http://www.nytimes.com/2007/09/11/business/media/11genetics.html. 
 100. Matthew Schulze, 25 Percent More States Allow Direct Access Testing, 32 LAB. MED. 
661, 661 (2001). In 1999, twenty-seven states allowed consumers direct access to testing; by 
2001, thirty-four states allowed direct access testing. Id. Thirty-seven states currently allow some 
form of direct-to-consumer testing. DTC STATUTE SURVEY, supra note 77. 
 101. See U.S. CONST. amend. X (reserving any powers not delegated to the Federal 
Government in the Constitution for the States). The regulation of health and safety matters is 
generally reserved for State consideration. Javitt et al., supra note 30, at 273. 
 102. See supra text accompanying notes 62–72. 
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of state regulation is also challenging because the majority of DTC genetic 
tests are offered to consumers through the Internet, and the companies that 
offer these tests may be outside the jurisdiction of any one state.103 
Additionally, many states have followed the precedent set by various 
federal agencies,104 and have not implemented specific regulations for DTC 
genetic tests.105  
B. Federal Regulation 
Three federal agencies have the greatest potential ability to regulate 
the DTC genetic tests currently available to consumers.106 The Food & 
Drug Administration (FDA) has authority to regulate medical devices used 
“in the diagnosis of disease or other conditions.”107 The Federal Trade 
Commission (FTC) has a statutory mandate to protect consumers and to 
prevent unfair or deceptive acts and practices, including false or misleading 
advertising.108 The Centers for Medicaid and Medicare Services (CMS) 
have authority to regulate medical testing within clinical laboratories under 
the Clinical Laboratories Improvement Amendments of 1988 (CLIA).109 
The regulatory authority of each agency is dependent on how each 
particular genetic test is produced, marketed, performed, and interpreted.110 
1. FDA Regulation 
In 2000, an official government advisory committee recommended 
that the “FDA should be the federal agency responsible for the review, 
approval, and labeling of all new genetic tests.”111 This committee also 
suggested that the FDA develop a review process that focuses on evaluating 
genetic test analytical and clinical validity, as well as evaluating clinical 
 
 103. Javitt & Hudson, supra note 13, at 64. See generally James R. Pielemeier, Why General 
Personal Jurisdiction Over “Virtual Stores” is a Bad Idea, 27 QUINNIPIAC L. REV. 625, 626 
(2009) (explaining that courts have begun to address whether a website can be sufficient contact 
for a state to assert jurisdiction). Although the D.C. Circuit and Ninth Circuit have found that an 
accessible website can create general jurisdiction, the Fourth, Fifth, Sixth, Tenth, and Federal 
Circuits have not found general jurisdiction in these cases. Id. at 626–27. 
 104. See discussion infra Part I.B. 
 105. See supra notes 77–87, 91–98 and accompanying text. 
 106. See Javitt et al., supra note 30, at 268 (introducing current federal regulation of genetic 
tests); Novick, supra note 11, at 624–30 (discussing the current regulatory structure). 
 107. 21 U.S.C. § 321(h)(2) (2006). 
 108. 15 U.S.C. §§ 45(a)(1)–(2) (2006). 
 109. Clinical Laboratory Improvement Amendments of 1988, Pub. L. No. 100-578, 102 Stat. 
2903 (1988) (codified at 42 U.S.C. § 263a). 
 110. Robertson, supra note 1, at 221. 
 111. SEC‟Y‟S ADVISORY COMM. ON GENETIC TESTING, NAT‟L INSTS. OF HEALTH, 
ENHANCING THE OVERSIGHT OF GENETIC TESTS: RECOMMENDATIONS OF THE SACGT 27 (2000), 
available at http://oba.od.nih.gov/oba/sacgt/reports/oversight_report.pdf. 
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utility claims made by the test developers.112 The Federal Food, Drug, and 
Cosmetic Act (FDCA) of 1938113 and the Medical Device Amendments of 
1976114 give authority to the FDA to regulate medical devices. A medical 
device is defined as “an instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar or related article, 
including any component, part, or accessory, which is . . . intended for use 
in the diagnosis of disease or other conditions, or in the cure, mitigation, 
treatment, or prevention of disease . . . .”115 
The FDA utilizes three categories of medical devices to determine how 
much control is needed to ensure the safety and effective use of each 
device.116 Class I devices are subject to the least FDA regulation oversight 
and may be introduced directly into U.S. commerce.117 Class II devices 
have an increased safety risk and are subject to greater FDA controls 
including post-marketing surveillance and device performance standards to 
ensure safety and effectiveness.118 Class III devices are defined as those: 1) 
for which general controls and special control would not provide reasonable 
assurance of safety and effectiveness; and 2) which are either for (a) 
supporting, sustaining, or preventing impairment of human health, or (b) 
present a potential unreasonable risk of illness of injury.119 Only a small 
number of predictive medical tests are classified and regulated as Class III 
medical devices; predictive personal genetic tests are generally not 
considered Class III devices.120 
Though the definition of a medical device provides the FDA broad 
authority to regulate genetic tests, the FDA has chosen to limit its regulation 
 
 112. Id. 
 113. 21 U.S.C. §§ 301–399 (2006). 
 114. Pub. L. No. 94-295, 90 Stat. 539 (1976) (codified in scattered sections of 21 U.S.C.). 
 115. 21 U.S.C. § 321(h)(2) (2006). The FDA has previously considered only some genetic tests 
in vitro diagnostic products. See Garcia, supra note 56, at 218 (explaining that the FDA considers 
certain complex genetic tests In Vitro Diagnostic Multivariate Index Assays (IVDMIA)). 
However, the FDA has recently decided to consider broader regulations for all laboratory-
developed genetic tests, instead of focusing on IVDMIAs. Oversight of Laboratory Developed 
Tests; Public Meeting; Request for Comments, 75 Fed. Reg. 34,463 (June 17, 2010); Turna Ray, 
FDA Shelves IVDMIA Final Guidelines in Order to Focus on Overall LDT Regulation, 
PHARMACOGENOMICS REP., June 17, 2010, http://www.genomeweb.com/dxpgx/fda-shelves-
ivdmia-final-guidelines-order-focus-overall-ldt-regulation. 
 116. Neil A. Holtzman, FDA and the Regulation of Genetic Tests, 41 JURIMETRICS 53, 59 
(2000). 
 117. 21 U.S.C. § 360c(a)(1)(A) (2006). 
 118. § 360c(a)(B). 
 119. § 360c(a)(C). 
 120. Bruce Patsner, New “Home Brew” Predictive Genetic Tests Present Significant 
Regulatory Problems, 9 HOUS. J. HEALTH L. & POL‟Y 237, 247 (2009). HIV tests are one of the 
few predictive medical tests regulated as Class III medical devices. Id. 
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of genetic tests.121 The limited regulation of new genetic tests may be due 
to the availability of the FDA‟s pre-market notification process.122 The pre-
market notification process, also known as 510(k) abbreviated marketing 
clearance, requires that developers “demonstrate that their new test is 
substantially equivalent to a medical device currently on the market.”123 If 
the genetic test developer can produce data that demonstrates that a new test 
is substantially equivalent to a test already available on the market, the new 
test can be marketed in the same class as that test, and the developer does 
not need to prove the new test‟s safety and effectiveness in order to gain 
pre-market approval.124 
The limited regulation of genetic tests may also be attributed to the 
FDA regulatory distinction between genetic “home brew” tests, which are 
developed and analyzed completely within one laboratory, and genetic tests 
that contain components that travel in interstate commerce.125 The FDA has 
chosen to regulate only the individual components and reagents used in the 
genetic tests, and has declined to regulate genetic “home brew” tests or the 
laboratories that develop and analyze them.126 Consequently, “home brew” 
tests are classified as Class I or II medical devices that are subject to less 
regulation than other genetic tests.127 Practically, this allows certain genetic 
tests to reach the consumer market without any FDA evaluation for safety, 
effectiveness, or accuracy.128 Consumers who purchase these DTC genetic 
tests “are likely unaware that the FDA is not involved in [any] quality 
manufacturing control or efficacy testing” of the products.129 
In addition to the self-imposed regulatory distinctions created by 
individual test development and components, the FDA has stated that its 
regulatory power over medical devices cannot be extended to regulate 
genetic tests marketed as services.130 This allows companies that market 
 
 121. See Robertson, supra note 1, at 223–24 (explaining that the FDA exercises “enforcement 
discretion” in the regulation of certain genetic tests). 
 122. See Solberg, supra note 58, at 730 (introducing the pre-market notification process). 
 123. Id. New Class III medical devices may be introduced to consumers through an 
abbreviated marketing application if the device is substantially equivalent to a device marketed 
prior to May 28, 1976, or to devices classified as class I or II since that date. Patsner, supra note 
120, at 246. 
 124. Holtzman, supra note 116, at 60. 
 125. Novick, supra note 11, at 629. 
 126. Patsner, supra note 120, at 251–52. See also Classification and Reclassification of 
Restricted Devices, Analyte Specific Reagents, 62 Fed. Reg. 62,243, 62,245 (Nov. 21, 1997) 
(discussing the FDA‟s intention not to regulate the reagents used in genetic tests differently from 
other class I medical devices). 
 127. Patsner, supra note 120, at 249. 
 128. Id. at 254. 
 129. Id. at 249–50. 
 130. Robertson, supra note 1, at 61. 
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their “home brew” tests as services to circumvent the entire FDA pre-
market approval process.131 
In addition to the market approval regulations, genetic tests may be 
subject to FDA regulations regarding medical device labeling.132 Genetic 
tests that include FDA regulated components must comply with the 
promulgated regulations regarding general medical device labeling,133 as 
well as with regulations for in vitro diagnostic products.134 The FDA is 
responsible for the regulation of advertising for restricted medical devices, 
however genetic tests that are classified as Class I or II medical devices are 
not considered restricted medical devices.135 DTC genetic tests and “home 
brew” test kits are generally not subject to these regulations, so the labels 
and materials included with these tests may include information that has not 
been substantiated.136 
2. FTC Regulation 
The FTC may have a better ability to regulate the advertising of 
genetic tests because the FTC has statutory authority to regulate the 
advertising of most medical devices.137 The FTC also has a statutory 
mandate to protect consumers and to prevent unfair practices and deceptive 
acts.138 The FTC considers three factors in determining if a practice is 
unfair: “1) whether the practice injures consumers; 2) whether it violates 
established public policy; and 3) whether it is unethical and 
unscrupulous.”139 An act is considered deceptive “if there is a 
misrepresentation, omission, or other practice, that misleads the consumer 
 
 131. Patsner, supra note 120, at 254. 
 132. Solberg, supra note 58, at 728. 
 133. 21 C.F.R. § 801 (2009). 
 134. 21 C.F.R. § 809.10 (2009). For example, the FDA requires that some genetic tests “state 
that their „[a]nalytic and performance characteristics are not established‟ . . . because they are „not 
clinically validated.‟” Jennifer E. Spreng, The Food and Drug Administration and the Pharmacy 
Profession: Partners to Ensure the Safety and Efficacy of the Pharmacogenomic Therapy, 13 J. 
HEALTH CARE L. & POL‟Y 77, 91–92 (2010). The result reports generated from these tests are also 
required to include a notification that the test is not cleared or approved by the FDA. Id. at 92.  
 135. See FDA Oversight of Direct-to-Consumer Advertising of Medical Devices: Hearing 
Before the S. Special Comm. on Aging, 110th Cong. (2008) [hereinafter FDA Oversight] 
(statement of Daniel Schultz, Director, Center for Devices and Radiological Health, Food & Drug 
Administration), available at http://www.fda.gov/NewsEvents/Testimony/ucm096272.htm 
(explaining that “few Class I and Class II devices are restricted by regulation”). 
 136. Solberg, supra note 58, at 729. 
 137. 15 U.S.C. §§ 52–55 (2006). See also FDA Oversight, supra note 135 (explaining that the 
FDA has authority to regulate restricted medical devices and the FTC has authority to regulate 
non-restricted medical devices). 
 138. 15 U.S.C. § 45(a)(1) (2006 & Supp. 2009). 
 139. FED. TRADE COMM‟N, FTC POLICY STATEMENT ON UNFAIRNESS (1980), available at 
http://www.ftc.gov/bcp/policystmt/ad-unfair.htm. 
WEBSITE final(2) 4/18/2011 12:02 PM 
2011] FILLING IN THE CRACKS S 17 
acting reasonably in the circumstances, to the consumer‟s detriment.”140 
The FTC is also primarily responsible for the regulation of Internet-based 
product advertising.141 FTC regulation is based on the content of the 
advertisement or speech.142 
Although the FTC has regularly taken action against a variety of health 
product manufacturers, the agency has not yet exercised this authority 
against any genetic test advertisement.143 This limited FTC action may be 
directly related to the FDA‟s limited regulation of DTC genetic tests as 
medical devices because the FTC often looks to the FDA‟s labeling 
requirements to determine if a particular test claim is false or misleading.144 
However, since the FDA has limited its regulation of genetic tests, the 
majority of such tests are made available to consumers without any need for 
efficacy validation.145 This affects the FTC‟s actions for claims about 
genetic test advertisements because, without a FDA standard, the FTC may 
not be able to clearly determine which DTC genetic test advertisements are 
false or misleading.146 Without an FDA standard, FTC action against DTC 
genetic test advertisements may also face increased First Amendment 
scrutiny because there is little basis for the clear determination that the 
claims are false or misleading.147 
3. CLIA and CMS Regulation 
CLIA148 establishes regulations to ensure that every laboratory 
determines the analytical validity of its laboratory tests before offering them 
for clinical purposes, such as use for disease diagnosis, prevention, or 
treatment.149 Although CLIA was enacted to certify valid and reliable 
medical testing, CLIA does not authorize or certify the validity of the 
individual tests.150 
 
 140. FED. TRADE COMM‟N, FTC POLICY STATEMENT ON DECEPTION (1983) [hereinafter FTC 
STATEMENT ON DECEPTION], available at http://www.ftc.gov/bcp/policystmt/ad-decept.htm. 
 141. Javitt & Hudson, supra note 13, at 65. 
 142. Javitt et al., supra note 30, at 286. 
 143. Javitt & Hudson, supra note 13, at 65. 
 144. Id. 
 145. Patsner, supra note 120, at 249–50. 
 146. Javitt & Hudson, supra note 13, at 65. 
 147. Id. 
 148. Clinical Laboratory Improvement Amendments of 1988, Pub. L. No. 100-578, 102 Stat. 
2903 (1988) (codified at 42 U.S.C. § 263a). 
 149. LABORATORY PRACTICES, supra note 2, at 3; Holtzman, supra note 116, at 57. For 
genetic tests, analytical validity refers to accurate identification of a particular genetic mutation. 
Javitt & Hudson, supra note 13, at 59. 
 150. Robertson, supra note 1, at 222. 
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CLIA imposes basic requirements for laboratory methodology and 
documentation and standards for personnel qualification in order for a 
laboratory to receive certification.151 CLIA certification also requires 
periodic facility inspections and the examination of proficiency sample tests 
for high complexity tests.152 Although genetic tests are highly complex and 
require precise skill to perform and interpret, CMS does not require 
laboratories that perform genetic testing to undergo specific proficiency 
examinations for the genetic tests.153 In addition, although laboratories that 
perform genetic tests must meet some personnel requirements to fulfill the 
certification requirements for high-complexity testing, the actual 
laboratories are still only subject to the general CLIA methodology and 
documentation requirements.154 Furthermore, CLIA “does not require [that] 
laboratories address the clinical validity or utility of tests [performed].”155 
This is particularly problematic for “home brew” genetic tests because 
CLIA does not include explicit authorization or a process for evaluating test 
accuracy.156 
Although CLIA requires that laboratories report any changes about 
offered examinations and procedures to the Secretary of Health and Human 
Services,157 CLIA does not authorize CMS to limit or restrict the offering 
of a particular test.158 The decision to offer new genetic tests is left to the 
discretion of each individual laboratory.159  
The Centers for Disease Control and Prevention (CDC) advises CMS 
on CLIA implementation, provides scientific and technical support for 
CMS, and sponsors the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) program.160 Recently, the CDC published new 
 
 151. 42 U.S.C. §§ 263a(d)(1), (e)(2)(D), (f)(1) (2006). 
 152. §§ 263a(d)(3), (f)(3)(A); Javitt & Hudson, supra note 13, at 59. This distinction means 
that “there are no specified quality control, personnel, or proficiency testing requirements 
mandated under the CLIA regulations for most genetic tests.” At Home DNA Tests: Marketing 
Scam or Medical Breakthrough: Hearing Before the S. Special Comm. on Aging, 109th Cong. 35–
36 (2006) (prepared statement of Kathy Hudson, Director, Genetics & Public Policy Center, and 
Associate Professor, Berman Bioethics Institute, Institute of Genetic Medicine and Department of 
Pediatrics, Johns Hopkins University). 
 153. Javitt & Hudson, supra note 13, at 59–61. 
 154. 42 C.F.R. § 493.1495 (2009); LABORATORY PRACTICES, supra note 2, at 3. 
 155. Holtzman, supra note 116, at 57. Clinical validity refers to whether the information 
provided is relevant to an individual‟s health and disease. Javitt & Hudson, supra note 13, at 59. 
Clinical utility refers to “the likelihood that use of a test will lead to an individual‟s improved 
health outcome.” Id. at 61. 
 156. Javitt & Hudson, supra note 13, at 61. 
 157. 42 U.S.C. § 263a(d)(2)(B) (2006). 
 158. Javitt & Hudson, supra note 13, at 61. 
 159. Id. 
 160. GENETICS & PUB. POL‟Y CTR., WHO REGULATES GENETIC TESTS? (Feb. 27, 2006, 
updated May 30, 2008), available at 
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recommendations for good laboratory practices for ensuring the quality of 
genetic testing.161 These recommendations address issues that develop 
throughout the entire genetic testing process and include guidelines for 
providing information and informed consent to users of the laboratory 
services, specimen submission and handling, test referrals, quality control 
procedures, proficiency testing, test reporting, and specimen and record 
retention.162  
In addition to advising CMS on the implementation of CLIA, the 
CDC, through the Human Genome Epidemiology Network (Network), may 
have the ability to determine the validity of genetic tests.163 By compiling 
anonymous samples and data on genetic test results, the Network could 
establish the frequencies of genotypes implicated in a variety of diseases to 
determine more reliable estimates of test validity.164 
II. HIV: A PAST EXAMPLE OF HOME TEST KIT CONTROVERSY 
Los Angeles public health officials reported the first cases of acquired 
immunodeficiency syndrome (AIDS) in 1981.165 By 1987, the CDC 
determined that the human immunodeficiency virus (HIV) caused AIDS, 
and that the disease was spread through exposure to infected blood.166 The 
CDC, in conjunction with state and local health departments, began a 
national public education campaign to combat the spread of the HIV and 
AIDS.167 Initial guidelines suggested that “[c]ounseling and testing persons 
 
http://www.dnapolicy.org/policy.issue.php?action=detail&issuebrief_id=10. The EGAPP program 
makes non-binding recommendations about the validity and utility of specific genetic tests based 
on systematic, evidence-based genetic test assessments. Id. 
 161. LABORATORY PRACTICES, supra note 2, at 1. 
 162. Id. at 7. 
 163. Holtzman, supra note 116, at 57. 
 164. Id. at 57–58. 
 165. Michael S. Gottlieb et al., Pneumocystis Pneumonia – Los Angeles, 30 MORBIDITY & 
MORTALITY WKLY. REP. 250 (1981), available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm. This report described the cases of a 
rare pneumonia in five previously healthy homosexual men. Id. at 250–51. The accompanying 
editorial note suggested that the disease was “related to a common exposure” and “acquired 
through sexual contact.” Id. at 251. 
 166. Ctrs. for Disease Control & Prevention, Dep‟t of Health & Human Servs., Perspectives in 
Disease Prevention and Health Promotion Public Health Service Guidelines for Counseling and 
Antibody Testing to Prevent HIV Infection and AIDS, 36 MORBIDITY & MORTALITY WKLY. REP. 
509, 509 (1987) [hereinafter Perspectives], available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00015088.htm. 
 167. Ctrs. for Disease Control & Prevention, Dep‟t of Health & Human Servs., HIV and AIDS 
– United States, 1981-2000, 50 MORBIDITY & MORTALITY WKLY. REP. 430, 433 (2001), 
available at http://www.cdc.gov/mmwr/PDF/wk/mm5021.pdf. 
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who are infected or at risk for acquiring HIV infection is an important 
component of prevention strategy.”168 
A. Debated Development of the Home Test Kit 
In 1986 and 1987, the FDA reviewed several applications for the 
manufacture of a HIV home test kit.169 The FDA found that the proposed 
kits were medical devices subject to regulation under the FDCA and 
determined that the kits were not eligible for 510(k) abbreviated marketing 
clearance.170 In 1988, the FDA decided to limit the marketing of HIV 
testing blood collection kits to those kits intended for professional use,171 
which effectively banned the development of a HIV home test kit.172 Critics 
of the home testing kits included the American Medical Association, the 
CDC, several congressmen, and many gay activists.173 These objectors 
argued that the home tests would produce inaccurate results, increase the 
risk of suicide, and minimize the importance of pre- and post-test 
counseling.174 
Though the ban continued for a number of years, in 1994 the FDA 
announced plans to reconsider the approval of HIV home test kits.175 This 
announcement indicated that the FDA might be receptive to the use of 
home HIV tests.176 Once again, the debate between objectors and advocates 
of the HIV home test focused on concerns for users‟ welfare and their 
understanding of the test process and results. Objectors to the home test 
challenged the accuracy of the tests and raised concerns about the potential 
harms that home testers would suffer without face-to-face pre- and post-test 
counseling.177 Because a key aspect of the HIV home test kit was the 
availability of anonymous testing, objectors also raised concerns about the 
 
 168. Perspectives, supra note 166, at 509. 
 169. Home Test Kits Designed to Detect HIV-1 Antibody, 54 Fed. Reg. 7279, 7280 (Feb. 17, 
1989). The proposed kits were to include instructions and equipment for sample collection, 
packaging materials for shipment to a laboratory for testing, and a confidential mechanism to 
receive the test results. Id. 
 170. Id. See also supra notes 122–24 and accompanying text (discussing the 510(k) 
abbreviated marketing clearance process). 
 171. Home Test Kits Designed to Detect HIV-1 Antibody, 54 Fed. Reg. at 7280. 
 172. Steven R. Salbu, HIV Home Testing and the FDA: The Case for Regulatory Restraint, 46 
HASTINGS L.J. 403, 403 (1995). 
 173. Alexi A. Wright & Ingrid T. Katz, Home Testing for HIV, 354 NEW ENG. J. MED. 437, 
438 (2006). 
 174. Bayer et al., supra note 19, at 1296–97; Wright & Katz, supra note 173, at 438. 
 175. Food and Drug Administration Advisory Committee Meeting; Amendment of Notice, 59 
Fed. Reg. 29,814, 29,814 (June 9, 1994). 
 176. Id.; Salbu, supra note 172, at 403–04. 
 177. See Bayer et al., supra note 19, at 1296–97 (raising a number of questions about use of the 
home test kit).  
WEBSITE final(2) 4/18/2011 12:02 PM 
2011] FILLING IN THE CRACKS S 21 
impact that home HIV testing would have on public health practices and 
policies that mandated the reporting of HIV infection to local and state 
registries.178 In contrast, supporters of the HIV home test argued that the 
availability of a home test would increase the number of people tested for 
HIV infection, which would lead to reductions in risk behaviors and curb 
the spread of HIV.179  
1. Test Accuracy Concerns 
On both occasions when the FDA considered the approval of a HIV 
home test, the safety and efficacy of the home test kit was one of the most 
contested issues.180 Opponents to home testing focused on the fact that 
society generally needs medical professionals because patients are unable to 
diagnose or treat themselves;181 the HIV home test raised concerns because 
it required patients to collect their own specimens for testing.182 The use of 
individual patient specimen collection also raised concerns about the 
effectiveness of the home test kits when compared to test products 
developed for clinical professional use.183 Objectors speculated that non-
professional individuals utilizing the test would compromise test accuracy 
through contamination or misuse.184 There was also concern that users 
would not use the kits in a timely manner so the test kits would expire or 
become outdated through the inability to register new viral mutations 
discovered as testing technology continued to develop.185 
2. Pre- and Post-Test Counseling and Treatment Concerns 
In addition to concerns about the safety and efficacy of the testing 
process, multiple concerns were raised about the need for individuals 
participating in HIV testing to receive appropriate pre- and post-test 
 
 178. Id. at 1298. See also William O. Fabbri, Note, Home HIV Testing and Conflict with State 
HIV Testing Regulations, 21 AM. J.L. & MED. 419, 419 (1995) (discussing approval of a home 
HIV test and various state HIV testing laws). 
 179. Fabbri, supra note 178, at 421–22; Kathryn A. Phillips et al., Potential Use of Home HIV 
Testing, 332 NEW ENG. J. MED. 1308, 1308 (1995). Researchers found that black and Hispanic 
respondents, people with potentially less access to health care and HIV testing, and people with 
less education and lower incomes were more likely to say that they would use home HIV tests. Id. 
at 1308–09. The researchers determined that this was a significant finding because “preventive 
services and other home tests are usually more likely to be used by people with higher incomes 
and more education.” Id. at 1309. 
 180. Salbu, supra note 172, at 413. 
 181. Id. at 412. 
 182. Bayer et al., supra note 19, at 1296; Salbu, supra note 172, at 412. 
 183. Salbu, supra note 172, at 415. 
 184. Fabbri, supra note 178, at 429. 
 185. Id.; Salbu, supra note 172, at 415. 
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counseling and treatment.186 Objectors worried that individuals who 
received a positive test result over the phone would be unable to handle the 
“death sentence.”187 There was also concern that individuals who received 
their test results over the phone would hang up before receiving necessary 
counseling.188 The objectors argued that the mandatory face-to-face pre- 
and post-test counseling that individuals received while getting clinical HIV 
testing was essential.189 Supporters of the HIV home test argued that the 
level of face-to-face counseling available at clinical offices and HIV-testing 
facilities was variable, and that some HIV-testing clinics provided little or 
no counseling at all.190 Supporters asserted that specialized HIV counselors 
would have the opportunity to provide a consistent level of counseling to 
those receiving positive results over the telephone.191 The supporters relied 
on the success of other telephone counseling services including suicide hot 
lines and already established AIDS hot lines.192 Furthermore, supporters of 
home testing maintained that certain individuals would prefer to deal with 
an anonymous counselor over the phone instead of face-to-face 
counseling.193 
B. An Approved Home Test Kit 
Despite the concerns raised by opponents and advocates, the FDA 
eventually approved the Home Access HIV-1 Test System on July 22, 
1996.194 This home test kit is intended for anonymous, self-use HIV testing 
 
 186. See generally Salbu, supra note 172, at 417–26 (grouping these concerns into four 
categories). 
 187. Fabbri, supra note 178, at 422–23. Some AIDS activists reinforced this concern by 
referencing the obituary of a man who had jumped off of the Golden Gate Bridge after learning 
that he was HIV-positive. Wright & Katz, supra note 173, at 438.  
 188. Fabbri, supra note 178, at 423. One of the greatest issues raised concerning individuals 
who would possibly not receive adequate counseling was the fact that the user would have a lack 
of knowledge regarding the possibility of false positive results. Id.  
 189. See Salbu, supra note 172, at 421–23 (outlining and responding to arguments that in-
person counseling is a necessary part of an effective HIV testing program). 
 190. Id. at 419–20. 
 191. Id. at 423–24. 
 192. Fabbri, supra note 178, at 424.  
 193. Id. This position was supported by evidence that a significant number of individuals who 
underwent HIV tests in a clinical setting did not return for their test results or counseling. Id. See 
also Barnard M. Branson, Home Sample Collection Tests for HIV Infection, 280 JAMA 1699, 
1701 (1998). Following the approval of the HIV home test kits, researchers determined that 97% 
of users called for results, whereas the average return rate of individuals to clinical settings for 
results was 67% in 1996, with a 51% chance of return to sexually transmitted disease clinics. Id.  
 194. Letter from Dr. Jay S. Epstein, Director, Office of Blood Research and Review, Ctr. for 
Biological Evaluation and Research, U.S. Food & Drug Admin., to Michael Wandell, Home 
Access Health Corp. (July 22, 1996), available at 
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/Premarket
ApprovalsPMAs/ucm091848.htm; U.S. Food & Drug Admin., Home Access HIV-1 Test System 
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by adults.195 The test kit requires that each user call a toll-free telephone 
number to register their unique eleven-digit code.196 During this phone call, 
the user “is asked to provide basic demographic data, . . . a history of prior 
HIV antibody testing, knowledge of prior test results, expected result from 
the current test, and risk factors for HIV infection.”197 After answering 
these questions, the user “listens to an automated, 5-minute educational 
session about the HIV-1 antibody test, HIV prevention, risk reduction 
behavior, and AIDS.”198 This registration process is available to the test 
user at any time, 24 hours a day, seven days a week.199 During this 
registration process, the user also has the option of speaking with a 
counselor or physician to discuss any questions or concerns.200 
After collecting their own blood specimens, users ship their samples to 
the Home Access Lab.201 Once the specimen reaches the lab, the blood 
sample is tested by “experienced technicians using the exact same test 
ordered by doctors‟ offices, hospitals and clinics, ensuring greater than 
99.9% accuracy.”202 Users retrieve their test results by calling a toll-free 
number and providing their unique eleven-digit code.203 The company 
states that “[a]ll clients with indeterminate or positive results receive the 
test results directly from a counselor.”204 In addition, a predetermined 
 
Summary of Safety and Effectiveness 1 (1996) [hereinafter Test System], available at 
http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/
PremarketApprovalsPMAs/ucm091849.pdf. The FDA also approved another home HIV test 
manufactured by Direct Access Diagnostics in 1996, however the company withdrew its product 
from the market due to “lack of demand.” Branson, supra note 193, at 1699.  
 195. Test System, supra note 194, at 1. Each kit includes: an instruction manual, an HIV/AIDS 
educational booklet in English and Spanish, two safety lancets, an alcohol wipe, a sterile gauze 
pad, a bandage, a safety lancet disposal container, a blood spot collection card pre-coded with a 
unique eleven-digit number, a foil return pouch containing a desiccant, a shipping container, and a 
pre-addressed, prepaid return envelope. Id. 
 196.  Id. at 2. The Direct Access Diagnostics test did not require a registration phone call and 
instead used a pamphlet included with the test kit to provide pre-test counseling information. 
Branson, supra note 193, at 1699. 
 197. Test System, supra note 194, at 2. Users are asked to provide their year of birth, sex, race, 
and zip code. Id. 
 198. Id. 
 199. The Home Access® HIV-1 Test System, HOME ACCESS HEALTH, 
http://www.homeaccess.com/HIV_RegisterStep1.asp (last visited Mar. 18, 2011). 
 200. Id.; Test System, supra note 194, at 2. 
 201. The Home Access® Express HIV-1 Test How it Works, HOME ACCESS HEALTH, 
http://www.homeaccess.com/ExpressHIV_How_Works.asp (last visited Mar. 18, 2011) 
[hereinafter How it Works]. The laboratory is FDA approved, CLIA certified, and accredited by 
the College of American Pathologists. Id. 
 202. Id. 
 203. Test System, supra note 194, at 2. Test results are available seven days after the user ships 
the specimen to the laboratory, unless the user purchases an “Express” test kit, in which case the 
results are available the next business day after shipping. How it Works, supra note 201. 
 204. Test System, supra note 194, at 3. 
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percentage of clients with negative results also receive test results from a 
counselor, while the remaining clients receive their negative test results 
from an interactive voice response system.205 All clients, regardless of their 
test results, are able to speak with counselors once their results become 
available.206 
As a counselor provides results to the home test user, he or she also 
evaluates each test user‟s “coping skills, availability of personal support 
networks, and ability to inform sexual/needle-sharing partners” of the test 
results.207 Clients with positive results are referred to local physicians, 
clinics, and public health services in order to facilitate notification and 
treatment.208 Counselors may also provide referrals to the National AIDS 
Hotline and other psychosocial services.209 
III. FILLING IN THE REGULATORY CRACKS 
The current patchwork system of DTC genetic test regulation does not 
adequately protect consumers from potentially suspect genetic tests.210 
Although health is generally considered an area of state regulation,211 
continuing to rely on individual state DTC genetic test regulation will create 
a further “patchwork of non-uniform requirements.”212 Furthermore, since 
the majority of DTC genetic tests are offered to consumers through the 
Internet, the companies that offer these tests may be outside the jurisdiction 
of any one state, which may make state regulatory enforcement difficult.213 
A more effective and comprehensive federal regulatory scheme is necessary 
to ensure that genetic tests are appropriately used to improve individual 
health.214 
A. FDA 
To improve the regulation of DTC genetic tests, the FDA should 
follow the precedent set by the agency‟s decisions about the requirements 
and regulation of home HIV test kits. The HIV home test is currently 
 
 205. Id. 
 206. Id. “Clients with negative results may speak with a counselor as often as three times in a 
30 day period after their results become available. Clients with positive results may speak with a 
counselor 6 times over 12 months after their results become available.” Id. 
 207. Id. 
 208. Id. at 3–4.  
 209. Id. at 4.  
 210. See supra text accompanying notes 11–15.  
 211. Javitt et al., supra note 30, at 273. 
 212. Javitt & Hudson, supra note 13, at 64. 
 213. Id. 
 214. Id. at 66. 
WEBSITE final(2) 4/18/2011 12:02 PM 
2011] FILLING IN THE CRACKS S 25 
regulated by the FDA as a Class III medical device.215 Similar classification 
of DTC genetic tests as Class III medical devices, in contrast to the current 
regulation of genetic tests as either Class I or Class II medical devices,216 
would be an appropriate way to ensure “that the FDA subjects [DTC 
genetic] tests to sufficient oversight without unnecessary burden.”217 
Though only a small number of predictive medical tests are currently 
regulated as Class III medical devices, the FDA has previously determined 
that HIV tests must undergo increased medical device regulation due to the 
possibility of dramatic health-related decisions based on the HIV test 
results.218 Genetic test results are used primarily for predictive purposes 
and have equally great implications for dramatic health-related decisions,219 
yet the FDA has limited regulation to certain tests and reagents.220 The 
FDA should acknowledge that the concerns currently being raised about the 
potentially dangerous use of DTC genetic test results are identical to the 
concerns raised in the 1990s about the use of HIV home test kits.221 
Concerns about an individual‟s use of DTC genetic test results without 
appropriate counseling may be addressed by the FDA imposing a 
counseling requirement, similar to that applied to HIV home test kits, for 
any individual who wishes to receive his DTC genetic test results.222 
Following the HIV home test example, DTC genetic test companies should 
be required to provide consumers access to telephone counseling pre- and 
post-genetic testing.223 The availability and use of pre- and post-test 
telephone counseling will ensure that the individual consumers receive all 
of the information necessary to make informed health decisions based on 
their genetic test results.224 
The availability of personalized telephone counseling may also help 
individuals who are interested in genetic testing but are concerned about the 
 
 215. Patsner, supra note 120, at 247. 
 216. Id. 
 217. Solberg, supra note 58, at 736. 
 218. Patsner, supra note 120, at 247. See also supra note 187. 
 219. See supra text accompanying note 41–45 and note 69. 
 220. Robertson, supra note 1, at 223. 
 221. See discussion supra Part II.A. 
 222. See supra text accompanying notes 199, 203–208. 
 223. At least one DTC genetic test company has acknowledged the need to provide consumers 
with greater counseling options. 23andMe Partner to Provide Genetic Counseling, GENOMEWEB 
DAILY NEWS, June 7, 2010, http://www.genomeweb.com/dxpgx/23andme-partner-provide-
genetic-counseling. 
 224. The use of specially trained counselors to provide the genetic test results to consumers 
over the phone may also address concerns that some physicians are insufficiently prepared to 
interpret what genetic results mean for a particular patient. See Gniady, supra note 42, at 2448. 
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confidentiality of their test results.225 The convenience and confidential 
nature of home genetic testing is likely to attract additional consumers.226 
Additional FDA regulation of DTC genetic tests will ensure that the genetic 
tests provided to consumers who wish to avoid traditional health care 
settings provide valid and useful results. Even though widespread use of 
home genetic tests may be limited because the tests are home collection 
kits,227 eventually home genetic testing may become as commonplace and 
as accepted as home-use pregnancy testing.228 
In order for home genetic testing to be utilized to its greatest potential, 
the FDA must clarify or eliminate the regulatory distinction between “home 
brew” genetic tests and genetic tests that contain components that travel in 
interstate commerce.229 This distinction and the 510(k) clearance process 
currently enable the majority of genetic tests to reach the consumer market 
without any evaluation for safety, effectiveness, or accuracy.230 
Reclassifying DTC genetic tests as Class III medical devices would 
alleviate this problem because all Class III medical devices are subject to 
the most stringent regulations.231 Furthermore, the classification of all DTC 
 
 225. See supra text accompanying notes 58–61. It is important to note that the information 
provided to DTC genetic test companies may not be covered under HIPAA regulations because it 
is unclear if DTC genetic test companies are considered health care providers. See Health 
Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936 (1996). 
In addition, GINA regulations may not apply unless the DTC genetic test company provides the 
consumer‟s genetic information to an employer or insurer. See Genetic Information 
Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881 (to be codified in scattered 
sections of 26, 29, and 42 U.S.C.). 
 226. Solberg, supra note 58, at 714–15. 
 227. A home collection kit requires that the consumer collect a sample at home and send the 
specimen to a laboratory for analysis. Salbu, supra note 172, at 416 n.65. The consumer does not 
have the ability, equipment, or skill necessary to analyze or interpret the test results without the 
assistance of a laboratory technician. The HIV home test and DTC genetic tests are both 
considered home collection kits. 
 228. The traditional home pregnancy test is considered a home-use test kit because the 
consumer is able to collect the specimen and interpret the test in the comfort of her own home. 
Since 2006, one HIV test manufacturer has been seeking approval for an over-the-counter HIV 
home-use test kit that will utilize saliva instead of blood. Wright & Katz, supra note 173, at 437–
39. This test “works like a home pregnancy test, except that it uses oral fluid instead of urine.” Id. 
at 437. This test technology is currently used in clinical settings but has not been approved for 
over-the-counter use. See id. at 439 (reporting use of the rapid tests in clinics). 
 229. See Novick, supra note 11, at 629. 
 230. Patsner, supra note 120, at 254. One could argue that genetic tests should not even be 
eligible for 510(k) clearance due to the complexity of the tests and the lack of a pre-1976 predicate 
device. However, this issue may soon be addressed because the FDA has recently released a plan 
to revamp the 510(k) submission process. Matt Jones, UPDATE: FDA Plans Streamlining 510(k) 
Process in 2011, GENOMEWEB DAILY NEWS, Jan. 20, 2011, 
http://www.genomeweb.com/dxpgx/update-fda-plans-streamlining-510k-process-2011. 
 231. See 21 U.S.C. § 360c(a) (2006) (setting out the requirements for all three classes of 
medical devices). 
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genetic tests as restricted Class III medical devices would subject these tests 
to stricter FDA labeling requirements.232 
B. FTC 
The current FDA regulatory scheme that separates “home brew” 
genetic tests from other DTC genetic tests limits the FTC‟s ability to pursue 
claims against DTC genetic companies that use unfair or deceptive practices 
in their advertisements.233 The FDA‟s different labeling requirements and 
regulations negatively impact the viability of any currently proposed FTC 
claim because there is no applicable standard to determine if a DTC genetic 
test advertisement is misleading.234 In order for the FTC to successfully 
pursue claims for deceptive acts and practices, the test company‟s 
misrepresentation, omission, or practice must be material to the consumer‟s 
decisions regarding the genetic test.235 Though claims and omissions 
related to health and safety are generally considered presumptively 
material,236 without a clear FDA standard, the FTC does not have an 
incentive to use its limited resources on claims that do not appear to be 
causing actual harm to a large number of people.237 
More comprehensive and clearly defined FDA regulations will enable 
the FTC to better embrace its statutory role and protect consumers from 
misleading genetic test advertisements.238 The classification of DTC 
genetic tests as Class III medical devices will impose standard regulations 
for labeling239 and will allow the FTC to clearly determine which test 
advertisements are false or misleading.240 Furthermore, a more clearly 
defined standard will limit the success of any First Amendment protected 
speech claims.241 
 
 
 
 232. See FDA Oversight, supra note 135 (explaining that the current FDA oversight of 
“medical device advertising is limited to a subset of medical devices.”). 
 233. See discussion supra Part I.B.2. 
 234. Javitt & Hudson, supra note 13, at 65. 
 235. FTC STATEMENT ON DECEPTION, supra note 140. 
 236. Id.; Javitt et al., supra note 30, at 283. 
 237. See Javitt et al., supra note 30, at 286 (explaining that the FTC has historically reserved 
its resources for cases where there is “a showing of concrete harm to consumers from the use 
of . . . products as a result of claims made in advertising.”).  
 238. See supra Part I.B.2. 
 239. See FDA Oversight, supra note 135. 
 240. Javitt & Hudson, supra note 13, at 65. 
 241. Id. 
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C. CLIA 
To fully fill in the regulatory cracks, better coordination and 
harmonization is also needed between CMS, the FDA, and the FTC.242 
Although CLIA was enacted to ensure the analytical validity of laboratory 
tests,243 the current regulations have limited effect because they only 
address the validity of the testing process and not the validity of the 
individual tests.244 Furthermore, the current CLIA regulations fail to 
impose any obligation on the laboratories to explain to patients the meaning 
of their test results or the limitations of specific tests.245 Though individual 
genetic test validity may be best addressed by more comprehensive and 
clearly defined FDA regulations, under CLIA the determination of 
performance specifications for genetic tests that have not been cleared or 
approved by the FDA will help ensure the clinical validity of these tests, 
regardless of how the FDA classifies or regulates them.246 The 
determination of clinical validity may also improve potential FTC action 
because better quality control will lead to improved reports and will allow 
the FTC to more clearly determine which test claims are false or 
misleading.  
The CDC should urge laboratories to apply and utilize the recently 
published recommendations for good practices for ensuring the quality of 
genetic testing. The implementation of proficiency testing for genetic tests 
can help laboratories “reduce analytic deficiencies, improve testing 
procedures, and take steps to prevent future errors.”247 Finally, the CDC 
should consider utilizing the Human Genome Epidemiology Network to 
establish more reliable estimates of validity based on genotype 
frequencies.248 
 
 242. See generally Letter from Todd E. Gillenwater, Vice President, Pub. Policy, Cal. 
Healthcare Inst., to U.S. Food & Drug Admin. (April 14, 2009), available at 
http://www.regulations.gov/search/Regs/home.html#documentDetail?R=0900006480953351 
(describing the different approaches and criteria currently considered under CLIA and by the FDA 
for ensuring test safety and effectiveness). In June 2010, CMS and the FDA signed a 
Memorandum of Understanding that acknowledged the need for greater collaboration between the 
two agencies. CTRS. FOR MEDICARE & MEDICAID SERVS. & U.S. FOOD & DRUG ADMIN., MOU 
225-10--0010, MEMORANDUM OF UNDERSTANDING BETWEEN UNITED STATES FOOD AND DRUG 
ADMINISTRATION AND CENTERS FOR MEDICARE & MEDICAID SERVICES (2010), available at 
http://www.fda.gov/aboutfda/partnershipscollaborations/memorandaofunderstandingmous/domest
icmous/ucm217585.htm. The agencies “agree[d] to work together to promote initiatives related to 
the review and use of FDA-regulated . . . medical devices . . . .” Id. 
 243. LABORATORY PRACTICES, supra note 2, at 3. 
 244. Robertston, supra note 1, at 222. 
 245. Javitt et al., supra note 30, at 271 (explaining that there are no regulations regarding what 
laboratories may say when promoting genetic tests.). 
 246. LABORATORY PRACTICES, supra note 2, at 12–14.  
 247. Id. at 5. 
 248. Holtzman, supra note 116, at 57. See also supra text accompanying note 164. 
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IV. CONCLUSION 
The unique nature of genetic information and the predictive purpose of 
genetic test results distinguish genetic information and genetic testing from 
other health information and diagnostic tests.249 Although genetic testing is 
one of the fastest growing areas of laboratory testing,250 proper use of this 
technology may be limited by the current patchwork regulatory scheme.251 
The National Institutes of Health recently announced the creation of the 
Genetic Testing Registry (GTR), a public database that will provide 
increased access to information about the availability, validity, and 
usefulness of genetic tests to researchers, consumers, health care providers, 
and the public.252 The GTR is intended to be a comprehensive resource that 
provides detailed information about genetic tests currently available to 
patients; however, the information included in the GTR will be provided 
voluntarily by the genetic test providers.253 Since the GTR is voluntary, it is 
uncertain if the genetic testing companies will participate and provide 
meaningful or useful information about their tests.254 
Although the GTR is a step in the right direction,255 a better way to 
ensure that researchers, consumers, health care providers, and the public 
have access to accurate genetic tests that provide meaningful results is to fill 
in the current regulatory cracks. The FDA‟s experience with home HIV 
tests provides a viable path for implementing regulatory improvements.256 
Revamped FDA regulations and improved coordination between the FDA, 
FTC, and CMS will help ensure the quality of all genetic tests and will 
provide patients and physicians with greater confidence in genetic testing. 
 
 
 249. Javitt et al., supra note 30, at 260. 
 250. LABORATORY PRACTICES, supra note 2, at 3.  
 251. Robertson, supra note 1, at 222. 
 252. Press Release, Nat‟l Insts. of Health, NIH Announces Genetic Testing Registry (March 
18, 2010), available at http://www.nih.gov/news/health/mar2010/od-18.htm. 
 253. Id. 
 254. The disclosure of some information may also be hampered by the NIH‟s expectation that 
the GTR will be used to “[f]acilitate genetic and genomic data-sharing for research and new 
scientific discoveries.” Id. 
 255. Press Release, Genetics & Pub. Pol‟y Ctr., Center Applauds NIH‟s Newly Announced 
Genetic Test Registry as an Important First Step (March 18, 2010), available at 
http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=138. 
 256. See discussion supra Part III.A. 
